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Epigenetic silencing of tumor suppressor genes is generally thought to involve DNA cytosine meth-
ylation, covalent modifications of histones, and chromatin compaction. Here, we show that silencing
of the three transcription start sites in the bidirectional MLH1 promoter CpG island in cancer cells
involves distinct changes in nucleosomal occupancy. Three nucleosomes, almost completely absent
from the start sites in normal cells, are present on the methylated and silenced promoter, suggesting
that epigenetic silencing may be accomplished by the stable placement of nucleosomes into previ-
ously vacant positions. Activation of the promoter by demethylation with 5-aza-20-deoxycytidine
involves nucleosome eviction. Epigenetic silencing of tumor suppressor genes may involve heritable
changes in nucleosome occupancy enabled by cytosine methylation.INTRODUCTION
CpG islands, which often occur at the transcription start
sites of cancer-relevant genes, have been the focus of
most studies on epigenetic silencing. CpG islands have
an alternative structure to bulk chromatin in normal cells
(Tazi and Bird, 1990). They are characterized by a lack of
cytosine methylation, low levels of histone H1, high levels
of histone acetylation, and hypersensitivity to DNaseI
which has been equated with nucleosome-free regions
(Mucha et al., 2000; Pfeifer and Riggs, 1991; Tazi and
Bird, 1990). Genome-wide analysis has shown that DNa-
seI-sensitive sites are often present in both the expressing
and nonexpressing states onmany autosomal genes (Mito
et al., 2007; Sabo et al., 2004). In a more specific case, the
start site of the maternally imprinted and repressed Igf2
gene is unmethylated and DNaseI hypersensitive to the432 Cancer Cell 12, 432–444, November 2007 ª2007 Elsevier Isame extent as the paternal gene, which is strongly ex-
pressed (Sasaki et al., 1992a). Theseandother data (Davey
et al., 2004) suggest that the ‘‘open’’ or permissive state of
CpG islands for potential transcription is mitotically herita-
ble. A promoter permissive for transcription may therefore
be kept nucleosome free, allowing it to become activated
by binding of appropriate transcriptional activators (Li
et al., 2007). A central goal of tumor biology is to under-
stand themechanisms bywhich this permissive chromatin
configuration is converted into a state that is permanently
repressed and nonpermissive for expression.
The most well-characterized heritable covalent change
at the start sites of CpG island promoters of tumor sup-
pressor genes is abnormal promoter methylation (Herman
andBaylin, 2003; Jones andBaylin, 2007).Much effort has
been spent on investigating additional epigenetic changes
such as covalent histone modifications responsible forSIGNIFICANCE
CpG islands are generally kept in an inherently ‘‘open’’ state independently of expression in normal cells and are
methylation free and sensitive to nuclease cleavage in chromatin. Silencing in cancer involves DNA methylation
and chromatin covalent and structural changes that are somatically heritable and contribute to the cancer pheno-
type. Using the MLH1 CpG island as an example, we show that the switch between the two heritable states in-
volves the complete absence or presence of nucleosomes at the three start sites of the bidirectional promoter. Cy-
tosine methylation may therefore ultimately lead to silencing, through the mediation of methylated DNA-binding
proteins and other chromatin modifiers, by enabling the stable presence of nucleosomes at the start sites of can-
cer-related genes.nc.
Cancer Cell
Epigenetic Silencing of the MLH1 CpG Islandaberrant gene regulation in cancer. Inactive, hypermethy-
lated promoters are associatedwith a closed or repressive
chromatin configuration, characterized by deacetylated
histones and a variety of inactive histonemarks. For exam-
ples, in colon and breast cancer cells, the silencing of
MLH1 (Fahrner et al., 2002; McGarvey et al., 2006) and
RASSF1A (Strunnikova et al., 2005) is associated with
deacetylated histone H3 and increased H3-K9 methyla-
tion. The objective of this study was to explore additional
determinants such as the role of nucleosomal occupancy
in CpG island silencing in cancer because this has been
implicated in transcriptional control in yeast, flies, and
humans (Bernstein et al., 2004; Heintzman et al., 2007;
Lee et al., 2004; Lieb and Clarke, 2005; Mito et al., 2005;
Ozsolak et al., 2007; Yuan et al., 2005).
We focused onMLH1, a key player in the DNAmismatch
repair system (Modrich and Lahue, 1996), which is fre-
quently silenced by promoter hypermethylation in various
cancers (Herman et al., 1998; Kanaya et al., 2003; Kane
et al., 1997; Murata et al., 2002; Xiong et al., 2001).
MLH1, which we determined to have two transcripts, 1a
and 1b, is a member of a class of bidirectional gene pairs
that are transcribed head-to-head on opposite strands,
comprising 10% of human genes (Adachi and Lieber,
2002; Lavia et al., 1987; Takai and Jones, 2004; Trinklein
et al., 2004).
Until recently, methods for examining nucleosome posi-
tioning have relied on methodologies that reveal only the
average state of a given promoter on all of the molecules
in a cell population. However, we were able to analyze
the scenario on individual molecules by using our high-
resolution, methylase-based single-promoter analysis
assay (MSPA), providing insights into the dynamics of
chromatin remodeling (Fatemi et al., 2005; Gal-Yam
et al., 2006). Our results, obtained in several cell lines
and confirmed by traditional methods, show remarkable
nucleosome depletion just upstream of each start site on
the activeMLH1 promoter, whereas the inactive promoter
is associated with nucleosome occupancy in a mitotically
heritable fashion.
We also show that nucleosomes are removed from
promoter molecules upon gene reactivation by demethy-
lation with 5-aza-20-deoxycytidine (5-aza-CdR). Thus,
our results provide strong evidence that epigenetic silenc-
ing of tumor suppressor genesmay involve the insertion of
nucleosomes into previously vacant positions.
RESULTS
Organization of the EPM2AIP1 and MLH1 Genes
The bidirectional genes EPM2AIP1 and MLH1 on human
chromosome 3p22.1 are located within a CpG island
that is 1.6 kb long and has a GC content of 57% and
a CpG observed/expected ratio of 0.80 (Takai and Jones,
2003) (Figure 1A). The transcription start sites of the two
genes were suggested to be 470 bp apart on the GenBank
website. However, 50-RACE analysis with mRNA isolated
from LoVo colon cancer cells (data not shown) established
that MLH1 has two transcription start sites (1a and 1b)Canspaced 309 bp apart, a distance that could accommodate
almost two nucleosomes, whereas EPM2AIP1 initiates
transcription at only one site, 321 bp upstream of the first
initiation site, 1a, of MLH1 (Figure 1A). The start site of
EPM2AIP1 was found to be 150 bp closer to MLH1
(1a) than indicated by the GenBank website; therefore,
the divergent transcription start sites are actually 321 bp
apart, a distance that could also accommodate approxi-
mately two nucleosomes. Dual luciferase reporter assays
confirmed that the promoter was indeed bidirectional (see
Figure S1 in the Supplemental Data available with this
article online).
Correlation of the Endogenous Methylation Status
of the Bidirectional Promoter and the Expression
Patterns of EPM2AIP1 and MLH1
To determine the relationship between the methylation
status of the bidirectional promoter and the expression
Figure 1. Correlation of theMethylation Status of the Bidirec-
tional Promoter and the Expression Patterns of EPM2AIP1
and MLH1
(A) The bidirectional promoter and the CpG island. Horizontal arrows
show the transcription start sites as established by 50-RACE analysis,
and black boxes show the respective first exons. Black tick marks in-
dicate CpG dinucleotides. The horizontal bar underneath the tick
marks represents the CpG island.
(B) The average methylation levels of three CpGs in the EPM2AIP1/
MLH1 promoter region were analyzed by Ms-SNuPE, and the expres-
sion of both genes was determined by RT-PCR in a normal LD419
human bladder fibroblast cell line and various human cancer cell lines.
b-ACTIN expression served as a control for the input amount of cDNA.
RT served as a negative control for the intronless gene, EPM2AIP1.cer Cell 12, 432–444, November 2007 ª2007 Elsevier Inc. 433
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Epigenetic Silencing of the MLH1 CpG Islandof the two genes, we used the quantitative methylation-
sensitive single-nucleotide primer extension (Ms-SNuPE)
assay (Bender et al., 1999) and RT-PCR in normal human
fibroblast cells and various colon and bladder cancer cell
lines. Normal human fibroblast LD419 cells and cell lines
with low methylation levels (LoVo, HCT116, T24, J82,
LS174T, LS123, HT29, and SW620) expressed EPM2AIP1
and both transcripts of MLH1 (Figure 1B). Conversely,
none of the transcripts was produced in the colon cell lines
SW48 and RKO, displaying promoter hypermethylation
(93% and 95%, respectively, Figure 1B). Treatment of
both cell lines (SW48 and RKO) with the demethylating
agent 5-aza-CdR for 24 hr (Jones and Taylor, 1980)
caused a decrease in the level of CpG methylation, with
a concordant reactivation of all three transcripts (Fig-
ure 1B). Thus, the endogenous methylation status of the
bidirectional promoter correlates quite well with the
expression patterns of both genes, as was also shown
by others (Shu et al., 2006).
The MLH1 Promoter Has Only One Highly
Positioned Nucleosome in Expressing Cells,
Whereas It Is Occupied by Nucleosomes
in Nonexpressing Cells
Because nucleosomal positioning and histone tail modifi-
cations play essential roles in transcriptional regulations
(Bernstein and Allis, 2005; Rice and Allis, 2001), we first
investigated chromatin structure at all three transcription
start sites by using the DNaseI hypersensitivity assay.
Nuclei from LD419 and RKO cells were treated with in-
creasing concentrations of DNaseI to obtain suitable
levels of digestion (Figure 2A).
Southern blot images revealed a region of hypersensi-
tivity in the lanes of minimally digested LD419 chromatin
samples (Figure 2B, lanes 2–4), which was mapped to
the EPM2AIP1/MLH1 1a promoter region. Interestingly,
another hypersensitive region corresponding to the region
upstream ofMLH1 1b was also detected at higher enzyme
concentrations (Figure 2B, lane 4). These patterns were
not detected in control naked DNA, suggesting the lack
of sequence preference of DNaseI for that region. At the
genomic level, compared to LD419 nuclei, RKO nuclei
were digested to a greater extent with higher concentra-
tions of DNaseI (Figure 2A, lanes 11–14). However, even
under such digestion conditions, at the specific loci exam-
ined, the 1399 bp DraI fragment persisted in lanes 11–14
(Figure 2B) without showing any discrete DNaseI hyper-
sensitivity. The region in RKO cells is therefore more
compact and inaccessible to DNaseI. Thus, the regions
just upstream of all three start sites are highly accessible
in expressing LD419 cells, but not in nonexpressing
RKO cells. The hypersensitive sites in LD419 cells may
suggest the lack of nucleosomes, as a result of changes
in chromatin structure correlated with the transcriptional
activity of the genes.
To confirm the nucleosome depletion suggested by
DNaseI footprinting, we examined the presence of nucle-
osomes in the promoter regions at the mononucleosomal
level. Nuclei from LD419 and RKO cells were partially434 Cancer Cell 12, 432–444, November 2007 ª2007 Elsevier Idigested withMNase, yielding molecules of various nucle-
osomal repeats. Nucleosomes from the digested nuclei
were then run on sucrose gradients to isolate fractions
enriched in mononucleosomes, and the DNA, derived
from themononucleosomes, was analyzed by quantitative
PCR by using eight primer sets positioned across the
region (Figure 3A). Consistent with the DNaseI results, in
expressingLD419cells, the regionbetween theEPM2AIP1
andMLH1 1a transcription initiation sites (TISs) (Figure 3A,
b–d) and the region of 150 bp just upstream ofMLH1 1b
TIS (Figure 3A, f) showed virtually no signals after PCR.
Interestingly, there is one, and only one, highly positioned
nucleosome in the MLH1 promoter (1a+1b), just down-
stream of the MLH1 1a TIS (Figure 3A, e), corresponding
Figure 2. Detection of Hypersensitive Sites by DNaseI Diges-
tion
(A) Genomic naked DNA and nuclei from LD419 and RKO cells were
treated with increasing concentrations of DNaseI, DNA from each
sample was then purified and treated with DraI, and the digestion
products were analyzed by Southern blot. Naked DNA, as a control,
was used to confirm the lack of sequence specificity of the enzyme. Di-
gested samples prior to DraI treatment were resolved by gel electro-
phoresis as shown.
(B) Southern blot analysis revealed DNaseI hypersensitivity in the EP-
M2AIP1/MLH1 promoter. On the left, drawn to scale, the 1399 bp DNA
fragment generated by DraI digestion, transcription start sites (arrows),
and the probe fragment (black box) are indicated. Numbers show the
distance in bp.nc.
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Epigenetic Silencing of the MLH1 CpG IslandFigure 3. Nucleosomal Depletion by Mononucleosomal DNA and ChIP Analyses
(A) Mononucleosomal DNA analysis. Nuclei from LD419 and RKO were digested partially with MNase, and the reaction mixture was run on a sucrose
gradient to isolate mononucleosomal DNA. Enrichment of mononucleosomal DNA was analyzed by real-time PCR by using primers specific for eight
regions (a–h), shown as black rectangles on the top of the figure.
(B) Distinct chromatin structures at the EPM2AIP1/MLH1 promoter in expressing LD419 and nonexpressing RKO and SW48 cells. ChIP analysis per-
formed with antibodies against histone H3 and acetylated histone H3. Immunoprecipitated DNA was analyzed by real-time PCR as described in (A).
The fraction of immunoprecipitated DNA was calculated as a percentage of input DNA. Results are shown as the mean (bar) ± SD of two or three
experiments from two independent chromatin preparations.to the region between two hypersensitive sites (Figure 2B,
lane 4). However, no analogous nucleosomal depletion
was observed in nonexpressing RKO cells (Figure 3A).
Taken together, these results argue that the promoter re-
gions just upstream of all three start sites are depleted of
nucleosomes in expressing LD419 cells, but are occupied
by nucleosomes in nonexpressing RKO cells.CanDistinct Chromatin Structures at the EPM2AIP1/
MLH1 Promoter in Expressing
and Nonexpressing Cells
Next, we used the chromatin immunoprecipitation assay
(ChIP) to validate the above-described results. Because
we wanted as high a resolution map as possible over the
relatively small region between the start sites, particularcer Cell 12, 432–444, November 2007 ª2007 Elsevier Inc. 435
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Epigenetic Silencing of the MLH1 CpG Islandattention was paid to ensuring that the fragments gener-
ated by chromatin sonication were of the order of 200 bp.
Consistent with the DNaseI and the mononucleosomal
DNA analyses, H3 occupancy was clearly lower in the
region between the EPM2AIP1/MLH1 1a start site in
expressing LD419 cells and was much higher in nonex-
pressing RKO and SW48 cells (Figure 3B, b–d). A zone of
nucleosomal depletion or a ‘‘dip’’ in histone H3 occupancy
was seen in the EPM2AIP1/MLH1 1a promoter region of
the expressing LD419 cells (Figure 3B, b–d). No prominent
dips were present in nonexpressing RKO and SW48 cells,
and H3 occupancy was higher in the EPM2AIP1/MLH1 1a
promoter region compared to LD419 (Figure 3B, b–d).
However, ChIP analysis did not detect the depletion of
the nucleosome upstream of the start site of MLH1 1b in
LD419 (Figure 3B, f), probably as a result of the limited res-
olution of sonication. Overall, histone H3 acetylation was
high in expressing LD419 and virtually none in RKO and
SW48 (Figure 3B, a–h). Remarkably, the H3 acetylation
pattern in LD419 recapitulated the patterns seen in the
H3andmononucleosomalDNAanalyses, showingaprom-
inent dip in the EPM2AIP1/MLH1 1a promoter and a lesser
dip in the region just upstream of MLH1 1b (Figure 3B,
LD419, regions b–d and f). Although many studies have
shown that promoter regions are often associated with
increased acetylation in active promoters without specific
references to H3 occupancy, our results indicate that the
increased acetylation is actually coupled with H3 enrich-
ment in regions surrounding the promoter (Figure 3B,
a and e).
To test the generality of these findings, the chromatin
structure of the BRCA1/NBR2 CpG island promoter was
also investigated. Consistent with theMLH1 promoter, nu-
cleosomal depletion was again seen in the unmethylated
promoter in expressing T47D and Caov3 cells (see Figures
S2, S3A, and S3B, regions R5 and R4).
We next used a high-resolution MSPA to footprint indi-
vidual DNAmolecules in theMLH1 promoter (Fatemi et al.,
2005; Gal-Yam et al., 2006; Kladde and Simpson, 1996).
Nuclei from expressing, unmethylated LD419 cells were
treated with M.SssI, which methylates all accessible
CpG sites in purified DNA, but is unable to methylate
CpG sites that are found within a nucleosome, or bound
by tight-binding transcription factors (Fatemi et al., 2005;
Gal-Yam et al., 2006; Kladde and Simpson, 1996). After
M.SssI treatment, bisulfite conversion of extracted DNA,
and PCR amplification of the promoter region, single
PCR products were cloned and sequenced to show the
accessibilities of individual DNA strands to the methylase.
As expected, the regions analyzed were virtually unme-
thylated before M.SssI treatment in untreated LD419 nu-
clei (Figure 4A). Control experiments showed that naked
DNA extracted from the same cells was almost completely
methylated by M.SssI treatment at the region under the
same experimental conditions used for nuclei, with no
preferential sites of methylation (Figure 4B). Analysis of
the M.SssI-treated nuclei revealed that the 321 bp region
between the two start sites (EPM2AIP1 and MLH1 1a) as
well as a region of 150 bp upstream of MLH1 1b were436 Cancer Cell 12, 432–444, November 2007 ª2007 Elsevierlargely accessible to M.SssI, as shown by the extensive
acquired methylation, indicating the absence of nucleo-
somes in these regions (Figure 4C). No nucleosome foot-
print was seen in 28 out of 30 promoter replicas analyzed
in the 321 bp region, and none were seen in any of the 27
molecules analyzed in the 150 bp upstream of MLH1 1b
(Figure 4C). Furthermore, there were two clear patches
of substantial inaccessibility, suggesting the presence of
nucleosomes downstream of theMLH1 1a and EPM2AIP1
start sites (Figure 4C, pink). Patches are defined as at least
two consecutively unmethylated sites flanked on each
side by at least two consecutively methylated CpG sites
(Fatemi et al., 2005). Patches at both the 50 and 30 ends
were also considered as nucleosomes on the basis of
the ChIP and mononucleosome experiments (Figures 3A
and 3B). In fact, a well-defined nucleosome was precisely
positioned in 93% (25/27) of molecules examined in the
region downstream of MLH1 1a (Figure 4C, pink).
Two inaccessible patcheswhose sizeswere too small to
qualify as nucleosomes were also detected. One patch of
30 bp was observed in the region between EPM2AIP1
and MLH1 1a, and another patch of 20 bp was also
detected in the region between MLH1 1a and 1b, which
may be unidentified protein-binding sites (Figure 4C,
blue). In addition, there was another region of substantial
inaccessibility downstreamofMLH1 1b that could indicate
another nucleosome, as also suggested by the high
enrichment in region g in Figure 3. Together, these results
suggest that, in expressing LD419 cells, the region be-
tween EPM2AIP1 andMLH1 1a is devoid of nucleosomes,
whereas there is precisely one nucleosome positioned
downstream of MLH1 1a, followed by another nucleo-
some-free region upstream of the MLH1 1b start site.
The nucleosome-free regions correspond to the hypersen-
sitive regions seen in the DNaseI assay (Figure 2B, lane 4)
and also to precisely the same regions with the lowest
enrichment seen in the mononucleosomal DNA analysis
(Figure 3A, regions b–d and f).
In addition, to verify that the nucleosome depletion
observed is not just cell line specific, the MSPA assay
was also applied to expressing T24 cells. Consistently,
the region between EPM2AIP1 andMLH1 1a was virtually
nucleosome free in 17 of 20 promoter replicas, as shown
by high levels of accessibility to M.SssI (see Figure S4B).
Nucleosome Eviction after 5-aza-CdR Treatment
Because the promoter in nonexpressing RKO cells was
occupied by nucleosomes, we were interested to see
the chromatin structural changes accompanying gene
activation. First, we quantified the level of expression of
the silenced genes after 5-aza-CdR treatment by using
quantitative RT-PCR. As found previously (Figure 1B), 24
hr of 5-aza-CdR treatment caused a concordant reactiva-
tion of all three transcripts at 72 hr after addition of the
drug (Figure 5A). Expression for all three transcripts was
sustained even 44 days after drug treatment, although
with a 3- to 7-fold decrease in the level of expression (Fig-
ure 5A). The decreased expression as a function of time
after treatment has been observed with other genesInc.
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Epigenetic Silencing of the MLH1 CpG IslandFigure 4. Accessibility of Native Chromatin to M.SssI at the EPM2AIP1/MLH1 Promoter Region in Expressing LD419 Cells
(A–C) Nuclei were extracted from expressing unmethylated LD419 cells and were then treated with M.SssI for 15 min, followed by bisulfite genomic
sequencing. Two independent bisulfite-sequencing reactions were done to avoid introducing a bias in the analyses. Four PCR products of different
sizes, indicated by the blue, dotted lines, were included in the analysis. (A) Untreated nuclei. (B) NakedDNA treatedwithM.SssI. (C) Nuclei treatedwith
M.SssI. Horizontal lines with circles indicate individual molecules that were sequenced after PCR amplification and cloning of bisulfite-treated DNA.
Solid circles, methylated CpG dinucleotides; open circles, unmethylated CpG dinucleotides. Pink bars indicate areas or patches that are inaccessible
to M.SssI, suggesting the presence of nucleosomes. Patches are defined as at least two consecutively unmethylated sites flanked on each side by at
least two consecutively methylated CpG sites (Fatemi et al., 2005). Blue bars show the putative protein-binding regions.activated by 5-aza-CdR treatment and is due to a gradual
resilencing effect (Bender et al., 1999).
We then analyzed the chromatin changes upon gene
activation by ChIP analysis of RKO cells 48 hr, 72 hr, and
44 days after 5-aza-CdR treatment. H3 acetylation was
minimal in untreated RKO cells, increased slightly by 48
hr, and rose substantially by several fold in every region ex-
amined 72 hr after drug treatment (Figure 5B, a–h), as seen
by others (Fahrner et al., 2002). Even 44 days after drug
treatment, the H3 acetylation was still maintained at levels
intermediate to those seen in untreated cells and after
72 hr in virtually all regions. Strikingly, after gene activation,
acetylation patterns recapitulated the scenario seen in the
mononucleosomal DNA analysis, showing a dip in the
EPM2AIP1/MLH1 1a promoter and a lesser dip upstream
of the MLH1 1b at all time points after treatment. Qualita-
tively, the changes in H3 acetylation levels correlate well
with the changes in gene expression levels.
We next applied the MSPA assay to detect chromatin
structural changes in RKO cells after gene activation
upon 5-aza-CdR treatment. We focused on the region be-
tween the EPM2AIP1/MLH1 1a start sites to simplify the
analysis, and almost all of the CpG sites in the promoter
were endogenously methylated in untreated RKO cellsCan(see Figure S5A). In accordance with the expected mech-
anism of action of the drug (Egger et al., 2004),62% (15/
24) of themolecules weremethylation free or had sporadic
residual methylation 72 hr after treatment (Figure 6A).
These molecules could potentially serve as substrates
for M.SssI, thus allowing us to search for new footprints
by using the MSPA mapping technology.
We first verified that naked DNA extracted from 5-aza-
CdR-treated cells could be fully converted to methylated
molecules by M.SssI. This was indeed the case, because
95% (20/21) of the sequencedmolecules were extensively
methylated after M.SssI treatment (see Figure S5B).
Therefore, residual 5-aza-cytosine in DNA did not compli-
cate the analysis by the generation of spurious patterns.
Nuclei prepared from 5-aza-CdR-treated cells were
exposed to M.SssI, and 45 molecules were sequenced
and analyzed (Figure 6B). A total of 27 clones (60%)
were almost completely methylated (total methylation
level of 91%), but these were noninformative because
we could not distinguish whether they represented parent
DNA molecules that had not been demethylated by the
drug or whether they had been remethylated by M.SssI.
However, 40% (18 of 45 clones) of the molecules had
probably become modified by M.SssI, because none ofcer Cell 12, 432–444, November 2007 ª2007 Elsevier Inc. 437
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Epigenetic Silencing of the MLH1 CpG IslandFigure 5. Chromatin Structural Changes upon Gene Reactivation by 5-Aza-CdR
RKO cells were treated with 5-aza-CdR and then harvested 72 hr and 44 days after drug addition for RT-PCR and ChIP analyses. (A) Quantitative RT-
PCR. Expression levels were normalized with b-ACTIN, which served as a control for the input cDNA. Aminus-RT control served as a negative control
for the intronless gene, EPM2AIP1 (data not shown). Results are shown as the mean (bar) ± SD of two PCRs from two independent cDNA prepara-
tions. (B) Histone H3 acetylation patterns by ChIP. Immunoprecipitated DNA was analyzed by real-time PCR as described (Figure 3B). The fraction of
immunoprecipitated DNA was calculated as a percentage of input DNA. Results are shown as the mean (bar) ± SD of two or three experiments from
two independent chromatin preparations.patterns resembled any of themolecules in RKO cells after
5-aza-CdR treatment (Figure 6A). In addition, there were
partially methylated molecules, which had modification
patterns not present before M.SssI treatment. Of these,
61% (11 of 18 clones) had protected patches (as previ-
ously defined), large enough to accommodate nucleo-
somes, and many of these patches had the diagnostic
150ormultiples of 150bpsize footprints of anucleosome
(Fatemi et al., 2005) (Figure 6B). These represent demethy-
lated molecules that still harbored nucleosomes in the
MLH1 promoter, whereas others strongly resembled the
patterns observed in expressing LD419 cells (Figure 4C),
with high levels of M.SssI accessibility between the tran-
scription start sites (Figure 6B, blue box).
These data were obtained by amplification of the region
including parent methylated molecules that had not been
demethyated by 5-aza-CdR treatment. Thus, to filter out438 Cancer Cell 12, 432–444, November 2007 ª2007 Elseviersuch noninformative molecules and further refine the anal-
ysis, selective primers were designed, and the reverse
primer was annealed only to unmethylated molecules in
order to obtain a better representation of informative pro-
moter replicas (Figure 6B, arrows underneath the blue
box). As controls, no PCR products were produced from
the amplification of the DNA from untreated RKO cells
(data not shown), whereas after 5-aza-CdR treatment,
only substantially unmethylated molecules were amplified
and cloned, confirming the specificity of the primers (see
Figure S5C).
Nuclei prepared from 5-aza-CdR-treated cells 72 hr
after drug addition were then exposed to M.SssI, and pro-
moter molecules were sequenced and analyzed by selec-
tive amplification (Figure 6C). Approximately 54% (20 of 37
molecules) had nucleosomal patches (as defined above)
(Figure 6C). These represent demethylated moleculesInc.
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Epigenetic Silencing of the MLH1 CpG IslandFigure 6. Eviction of Nucleosomes by 5-Aza-CdR Treatment
(A–E) RKO cells were treated with 5-aza-CdR for 24 hr and were harvested 72 hr and 44 days after drug treatment started. Both DNA and nuclei from
drug-treated RKO cells were extracted and then subjected toM.SssI treatment, followed by bisulfite genomic sequencing. (A and D) Demethylation of
the promoter in RKO cells (A) 72 hr and (D) 44 days after addition of 5-aza-CdR. (B) Accessibility of native chromatin toM.SssI at the EPM2AIP1/MLH1
1a promoter region in RKO cells 72 hr after drug addition. To filter out extensively methylated molecules that were not suitable for M.SssI treatment,
PCR analyses were done with selective primers that only anneal to unmethylated molecules. See the main text for rationale. (C and E) M.SssI treat-
ments on nuclei from drug-treated RKO cells (C) 72 hr and (E) 44 days after drug addition, followed by bisulfite genomic sequencing with selective
primers. Please refer to Figure 4 for descriptions of molecules and patches. The DNAmolecules with nucleosome depletion in the promoter region are
boxed in blue.that still harbored nucleosomes in theMLH1 promoter. In
contrast, a second subset of promoter had high levels of
M.SssI accessibility between the transcription start sites,
flanked by inaccessible areas, indicative of a nucleo-
some-depleted region reminiscent of the patterns seen
in the expressing cells (Figure 6C, blue box, compared
to Figure 4C). Thus, the data strongly suggest that, at least
in a subset of promoters, the nucleosomes are evicted
when the genes become reactivated after drug treatment.
As for the demethylated promoters that seemed to be
occupied by nucleosomes, these could possibly reflect
hemimethylated promoter molecules that are still present
72 hr after drug addition according to the drugmechanism
(Bender et al., 1999; Egger et al., 2004); thus, nucleo-
somes might be trapped on the hemimethylated DNA
(Figure 6C).
To eliminate this variable, identical analyses were done
on RKO cells treated with 5-aza-CdR, followed by 44 days
of culture without the drug, at which time no or very littleCanhemimethylated DNA would be expected to be present.
Bisulfite genomic sequencing revealed that 7% (2/29)
of the sequenced molecules were still completely unme-
thylated, whereas the rest were extensively methylated
(Figure 6D), probably due to remethylation after removal
of the drug (Bender et al., 1999).
Again, only substantially unmethylated molecules were
detected by selective amplification from 44 days after 5-
aza-CdR treatment (see Figure S5D). Among them,
92% (12/13) had extensive accessibility to M.SssI
between the transcription start sites, indicative of a nucle-
osome-depleted region, recapitulating the patterns seen
in expressing cells (Figure 6E, blue box). These results
show that nucleosomes are evicted from a subset of
promoters upon gene reactivation by drug-induced meth-
ylation. Not only that, data from 44 days indicate that
nearly all of the demethylated promoter molecules lack
nucleosomes, establishing the heritability of nucleosomal
eviction on the demethylated, active promoter.cer Cell 12, 432–444, November 2007 ª2007 Elsevier Inc. 439
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Epigenetic Silencing of the MLH1 CpG IslandFigure 7. Correlation between the Expression Level and the Percentage of Nucleosome-Depleted Molecules
Data were graphed based on the results from Figures 5, 6, and 7. A decrease in expression is associated with a reduced nucleosome-depleted pop-
ulation.By combining the data from quantitative RT-PCR and
the MSPA analyses (Figures 4–6), we found a remarkable
correlation between the expression level and the percent-
age of nucleosome-depleted molecules for MLH1 1a and
EPM2AIP1, where the decrease in expression is associ-
ated with a reduced nucleosome-depleted population
(Figure 7). Thus, it seems very likely that reactivation of
such an epigenetically silenced gene requires nucleo-
some depletion in addition to demethylation of DNA and
the application of positive histone marks.
DISCUSSION
We set out to determine how the permissive chromatin
configuration of CpG islands, which is inherited indepen-
dently of transcriptional activity, is converted into a somat-
ically heritable silent or nonpermissive state. Depletion of
nucleosomes just upstream of transcription start sites
has recently been observed in genome-wide screens of
yeast, flies, and humans (Heintzman et al., 2007; Lee
et al., 2004; Mito et al., 2005; Ozsolak et al., 2007). This
strongly suggests that lack of nucleosomes is needed to
allow access of the transcriptional machinery to the per-
missive promoter (Li et al., 2007). Indeed, nucleosomal
remodeling factors have been shown to be causally linked
to transcription activation; for example, nucleosomes in
the PHO5 promoter are completely disassembled upon
transcriptional activation in yeast (Boeger et al., 2004). It
therefore seems likely that the absence of at least one
nucleosome is necessary for gene transcription. However,
we should again emphasize that many autosomal CpG
islands in human cells are in an apparently permissive
configuration, implying that nucleosomes are constitu-
tively depleted at start sites (Sabo et al., 2004; Sasaki
et al., 1992a).
Our results, obtained with a complex human promoter,
build on these studies in several important ways. First,
the high-resolution MSPAmethod, validated by traditional
approaches, shows that there is a constitutive complete
absence (i.e., total depletion) of a single nucleosome up-
stream of each start site. This is similar to what we saw in
the GRP78 promoter, in which no trace of a nucleosome
was seen in 356 promoter replicas we examined (Gal-Yam
et al., 2006). While it is possible that this might be due to440 Cancer Cell 12, 432–444, November 2007 ª2007 Elsevier Ina rapid and reversible nucleosomal occupancy, we think
this is unlikely because fixation with formaldehyde before
ChIP analysis confirmed very lowoccupancy in the regions
examined.With regard to the generality of our findings, our
results at theBRCA1/NBR2promoterwere consistentwith
those at theMLH1 promoter, suggesting that nucleosome
depletion in the CpG islands is quite common.
Second, we find it remarkable that the entire 630 bp pro-
moter, which generates three transcripts, acts as a unit in
the sense that either all transcripts were present or none
were present; thus, the start sites seem to be coordinately
controlled. Equally remarkable is the presence of a highly
positioned, acetylated nucleosome in almost all of the
promoter replicas in expressing cells. CpG islands often
do not have TATA boxes and thus initiate transcription in
quite a heterogeneous fashion. Our finding might help
explain the existence of multiple transcription start sites
in many mammalian CpG island promoters. Perhaps nu-
cleosome occupancy near the start sites is responsible
for defining the transcripts generated in a given CpG is-
land. Support for this idea comes from our observations
of a high level of positional variation and heterogeneous
start sites in the p16(INK4A) gene (Fatemi et al., 2005) in
contrast to the three ‘‘sharply defined’’ sites observed
by 50-RACE in MLH1. Further work will clearly be neces-
sary to resolve these issues.
The third implication of our work relates to the role of
occupancy in epigenetic silencing, which is, by definition,
mitotically heritable. Most work to date has focused on
constitutively active genes or on the chromatin changes
associated with gene induction. As an extension of a pre-
vious study on p16(INK4A) shows that DNA methylation
may serve to lock in the repressed state after H3-K9meth-
ylation (Bachman et al., 2003), our data suggest that
heritable DNA methylation patterns may maintain silenc-
ing by contributing to heritable changes in nucleosome
occupancy via positioning nucleosomes at the start sites.
The almost ‘‘digital’’ quality of this process was seen in our
experiments with 5-aza-CdR. Here, the erasure of DNA
methylation by drug treatment led to the reactivation of
all three start sites, application of the covalent activating
acetylated marks, and removal of the nucleosomes from
the region examined. Interestingly, the MLH1 promoter
had already adopted the ‘‘dip’’ conformation for histonec.
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Epigenetic Silencing of the MLH1 CpG IslandFigure 8. A Simplified Model for the Epi-
genetic Silencing of the MLH1 Gene
The active promoters of 1a and 1b are depleted
of at least one nucleosome just upstream of
each of the transcription start sites. In the si-
lenced state, the inactive promoters of 1a and
1b are occupied by nucleosomes. Treatment
with 5-aza-CdR causes substantial DNA de-
methylation of the promoter region, although
some molecules remain methylated. While
some hemimethylated promoter molecules may
still be occupied by nucleosomes, the nucleo-
some-free zone is established in some of the
promoter molecules. The activation of genes
is probably derived from these molecules
with a nucleosome-free zone in the promoter,
although we could not determine this defini-
tively. Green represents nucleosomes bearing
active marks. Red represents nucleosomes
bearing repressive marks. Gray represents
nucleosomes occupying the region of hemime-
thylation. Open circles indicate unmethylated
CpG dinucleotides, and filled circles represent
methylated CpG dinucleotides. Hemimethyl-
ated DNA is shown as half-filled circles. Ac
refers to acetylated histone tails.H3 acetylation 48 hr after drug treatment started. How-
ever, we have not as yet determined whether histone
modifications precede the nucleosomal rearrangement,
or whether the active marks are applied to the rearranged
nucleosomes. Nonetheless, even though the gene was
resilenced as a function of time after treatment, the 7%
of promoters that remained unmethylated in the mass
population were also nucleosome free. Indeed, the level
of expression of all three transcripts in reactivated RKO
cells was highly correlated with the level of nucleosome
deficiency.
Thus, we suggest a model of the epigenetic silencing of
theMLH1 gene in which the unmethylated and active pro-
moters ofEPM2AIP1 andMLH1 (1a and1b) aredepletedof
one nucleosome just upstream of each of the transcription
start sites (Figure 8). In the silenced state, the methylated
and inactive promoters are occupied by nucleosomes,
and treatment with 5-aza-CdR causes considerable DNA
demethylation of the promoter region, although some
molecules remain methylated. Remarkably, while some
hemimethylated promoter molecules are occupied by nu-
cleosomes, the nucleosome-free zone is established in
a substantial portion of the promoter molecules. Because
these promoter molecules show strikingly similar patterns
to those seen in expressing cells (Figure 4C), they areprob-
ably associated with the reexpression of genes (Figure 8).CanConversely, the genes aremost likely silenced in the hemi-
methylated promoter molecules that have nucleosomes in
the promoters because hemimethylation has been shown
to block transcription by inhibiting transcription factor
binding (Sasaki et al., 1992b).
Our data are consistent with earlier studies showing that
unmethylated CpG islands are nuclease accessible,
whereas methylated counterparts are occupied by ran-
domly positioned nucleosomes (Patel et al., 1997; Pfeifer
and Riggs, 1991). However, these studies relied on rela-
tively low-resolution nuclease digestions or in vivo foot-
printing, whereas we were able to show this digitally with
our high-resolution assay. The transition from the inactive
to the active state, after gene reactivation by 5-aza-CdR,
seems to involve nucleosome eviction. Our model is
supported by a study by Kass et al. (1997) that showed
mechanistically that a methylated CpG island promoter,
but not its unmethylated counterpart, forms nucleosomal
arrays after injection into Xenopus oocytes. This study,
done in an artificial system, complements our findings
and potentially provides a mechanistic basis for what we
see in cancer cells.
Methyl-binding proteins such as MBD1, MBD2, or
MeCP2 are likely to be involved in silencing of methylated
promoters (Klose and Bird, 2006), and we have docu-
mented the presence of MeCP2 at methylated CpGcer Cell 12, 432–444, November 2007 ª2007 Elsevier Inc. 441
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Epigenetic Silencing of the MLH1 CpG Islandislands associated with tumor suppressor genes (Nguyen
et al., 2001, 2002). Thus, it is conceivable that MeCP2 and
other methylated binding proteins stabilize the presence
of nucleosomes inmethylated promoters. Direct structural
changes in the properties of the DNA helix elicited by
methylation might also directly alter occupancy (Pennings
et al., 2005). Which mechanism predominates is unclear;
nevertheless, our data suggest that the core mechanism
responsible for permanent silencing may be the insertion
of a nucleosome into a previously unoccupied site. Al-
though the exact chromatin remodeling complex regulat-
ing the eviction of nucleosomes that we observed has not
been identified, nucleosomal occupancy might be the
essential outcome of a chromatin remodeling process




Colorectal cancer cell lines (LoVo, HCT116, LS174T, LS123, HT29,
SW620, SW48, RKO), bladder cancer cell lines (T24, J82), and a cervi-
cal cancer cell line (HeLa) were obtained from the American Type
Culture Collection (ATCC). All cells were cultured as recommended
by the ATCC. A normal LD419 human bladder fibroblast cell line was
generated in our laboratory and cultured in McCoy’s 5A supplemented
with 20% FBS.
5-Aza-20-Deoxycytidine Treatment
Cells were plated (43 105 cells/100 mm dish or 23 106 cells/150 mm
dish), and 24 hr later, they were treated with 105 M 5-aza-20-deoxycy-
tidine (Sigma) for 24 hr. The culture was then replenished with fresh
medium without the drug for 2 more days, and then nuclei, DNA, and
RNA were isolated from the drug-treated culture.
Methylation-Sensitive Single-Nucleotide Primer Extension
Genomic DNA was treated with sodium bisulfite as previously de-
scribed (Frommer et al., 1992). The mean cytosine methylation levels
of CpG sites were determined by the methylation-sensitive single-
nucleotide primer extension assay as described previously (Nguyen
et al., 2001). All primer sequences are available upon request.
RT-PCR
Total RNA was isolated from cells with the Trizol reagent (Invitrogen).
Reverse transcription was performed with random primers. The 50-30
sequences of the primers used in the PCR are: b-ACTIN forward,
TTTGAGACCTTCAACACCCCAG; b-ACTIN reverse, TTTCGTGGAT
GCCACAGGA; MLH1 forward, CAGCTAATGCTATCAAAGAGATGAT
TG (1a) and GAGACCTTTTAAGGGTTGTTTGG (1b); MLH1 reverse,
GTTGTAAGAGTAACATGAGCCACATG; EPM2AIP1 forward, TTTG
TGGCCTATGAGAACTACC; EPM2AIP1 reverse, GCTCTGATTCAG
ATTCCGTTAG. The PCR conditions were 95C for 9 min, 30 cycles
(25 cycles for b-ACTIN) of 95C for 30 s, 62C for 1 min, 72C for
1 min, and 72C for 10 min. PCR products were resolved on 2% aga-
rose gels. Quantitative RT-PCR was performed with an Opticon light
cycler with SYBR green I (Sigma), by using the primers listed above.
All values were normalized to b-ACTIN expression ratios, and a set
of known amounts of standards was used for quantitation.
Bisulfite Genomic Sequencing
DNA extracted from cells were treated with bisulfite, were PCR ampli-
fied with primers specific to the bisulfite-converted DNA, and then
ligated into the pGEM-T easy vector (Promega). For MLH1 1a, three
PCR amplifications of DNA sizes of 250, 536, and 708 bp were
produced. For MLH1 1b, a PCR amplification of DNA size of 416 bp442 Cancer Cell 12, 432–444, November 2007 ª2007 Elsevier Inwas produced. Primer sequences and PCR conditions are available
upon request. In addition, the selective amplification in the MSPA as-
say on RKO cells was performedwith the reverse primer only annealing
to the unmethylated molecules to eliminate the amplification of exten-
sively methylated clones that could not be analyzed (see the main text
for rationale). To increase the specificity of the primer to unmethylated
DNA, a mismatch was incorporated at the 30 end of the reverse primer,
which will destabilize unspecific duplex formation. For selective ampli-
fication, the 50-30 sequences of the primers were as follows: forward,
TGGGTTGGAAAATTAGAGTTTTGTT; reverse, ACCAAATAACCCCT
ACCACAAATA. Individual plasmid molecules were sequenced by an
automated DNA sequencer at Laragen (LA) and at the microchemical
core laboratory at the University of Southern California (USC).
Rapid Amplification of cDNA Ends, 50-RACE
Total RNA was extracted from LoVo cells as described above, and the
50 ends of mRNA were determined by using the RLM-RACE Kit (Am-
bion) according to the manufacturer’s instructions. 50-RACE reaction
products were cloned into a pGEM-T easy vector (Promega) and
sequenced.
M.SssI Treatment
Nuclei preparation and M.SssI reactions were performed as described
previously (Fatemi et al., 2005). Briefly, purified genomic DNA and
freshly extracted nuclei were treated with M.SssI for 15 min at 37C.
Reactions were stopped by the addition of an equal volume of stop so-
lution (20 nM Tris-HCl [pH 7.9], 600 mM NaCl, 1% SDS, 10 mM EDTA,
400 mg/ml proteinase K), incubated at 55C overnight, and DNA was
purified by phenol/chloroform extraction and ethanol precipitation.
DNaseI Footprinting
Nuclei from LD419 cells were extracted as described above. Nuclei
were resuspended in RSB buffer (10 mM Tris-HCl [pH 7.4], 10 mM
NaCl, 3 mM MgCl2) plus 0.25 M sucrose and were then incubated
with various concentrations of DNaseI (Worthington) at 37C for
15min to obtain a suitable range of digestion of genomic DNA revealed
by EtBr staining. Digested DNA, purified as described above, was cut
again by the DraI restriction enzyme to be resolved on a 1.5% agarose
gel, which was then Southern blotted. The blot was hybridized with
a 163 bp PCR-amplified DraI probe spanning 29 to 134 bp relative
to MLH1 1b. The probe was labeled with [a-32P]dCTP by using High
Prime (Roche #0) and was hybridized by ExpressHyb Hybridization
Solution (BD Biosciences). The 50-30 PCR primer sequences
used for the probe amplification were as follows: forward, GTTC
CCTGACGTGCCAGTCA; reverse, AAATTAAGTGGCTTCCTTACTTA
GTTAACG. The blot was visualized by Molecular Dynamics Phos-
phorImager.
Mononucleosomal DNA Preparation and Analysis
Detailed protocols were published previously (Gal-Yam et al., 2006).
Quantitative PCR was performed by using AmpliTaq Gold DNA poly-
merase (Applied Biosystems) and SYBR green I with the DNA Engine
Opticon System (MJ Research, Cambridge, MA). The primer se-
quences are available upon request. The following PCR conditions
were used: 95C for 9 min, and 45 cycles of 95C for 30 s, 62C for
1 min, and 72C for 1 min, followed by 72C for 10 min. The values
were normalized with naked DNA.
ChIP Assays
ChIP analyses were performed as described previously (Nguyen et al.,
2001). The following antibodies were used: 10 ml of either anti-Histone
H3 (Abcam) or anti-acetylated Histone H3 (Upstate) and 1 ml rabbit IgG
(Upstate) as a nonspecific antibody control.
Real-Time PCR Amplification of Immunoprecipitated DNA
Quantitative PCR was performed by using AmpliTaq Gold DNA poly-
merase (Applied Biosystems) and TaqMan probes (Biosearch) with
the DNA Engine Opticon System (MJ Research, Cambridge, MA).c.
Cancer Cell
Epigenetic Silencing of the MLH1 CpG IslandThe primers and probe sequences are available upon request. The
following PCR conditions were used: 95C for 10 min, and 45 cycles
of 95C for 15 s and 59C for 1 min. For each PCR, a set of known
amounts of DNA was included as a quantitation standard, and immu-
noprecipitated samples with nonspecific antibody were also included.
The fraction of immunoprecipitated DNA was calculated as a percent-
age of input DNA.
Supplemental Data
The Supplemental Data include the promoter deletion analysis of the
EPM2AIP1/MLH1 1a promoter and additional data on the BRCA1/
NBR2 promoter, as well as five supplemental figures, and can be found
with this article online at http://www.cancercell.org/cgi/content/full/
12/5/432/DC1/.
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